Evidence map›Paper›PMID 42239270›Full record

ArticlebioRxiv : the preprint server for biology2026

T-cell Receptor (TCR) Targeting with Multivalent T-cell Engagers.

Debasmita Paul, Abhishek Kulkarni, Freddys Rodriguez, Declan G Dahlberg, Lakmal Rozumalski, Carston R Wagner

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Debasmita PaulUniversity of Minnesota, Department of Medicinal Chemistry, 2231 6th Street S.E. Cancer & Cardiovascular Research Building Minneapolis, Minnesota 55455, USA.
Abhishek KulkarniUniversity of Minnesota, Department of Medicinal Chemistry, 2231 6th Street S.E. Cancer & Cardiovascular Research Building Minneapolis, Minnesota 55455, USA.
Freddys RodriguezUniversity of Minnesota, Department of Medicinal Chemistry, 2231 6th Street S.E. Cancer & Cardiovascular Research Building Minneapolis, Minnesota 55455, USA.
Declan G DahlbergUniversity of Minnesota, Department of Medicinal Chemistry, 2231 6th Street S.E. Cancer & Cardiovascular Research Building Minneapolis, Minnesota 55455, USA.
Lakmal RozumalskiUniversity of Minnesota, Department of Medicinal Chemistry, 2231 6th Street S.E. Cancer & Cardiovascular Research Building Minneapolis, Minnesota 55455, USA.
Carston R WagnerUniversity of Minnesota, Department of Medicinal Chemistry, 2231 6th Street S.E. Cancer & Cardiovascular Research Building Minneapolis, Minnesota 55455, USA.ORCID 0000-0001-7927-719X

Funding

Targeting Effector Immune cells to Cancer with Chemically Self-Assembled Nanorings (CSANs)R01CA247681 · NCI · UNIVERSITY OF MINNESOTA · PI WAGNER, CARSTON R. · 2020 to 2024
$2.8M
NCI NIH HHS R01 CA247681
6 · The paper itself

Abstract

T-cell engagers (TCEs) for cancer immunotherapy have traditionally relied on high affinity single chain fragment variable (scFv) domains to target CD3, specifically the ε chain, for the activation of T-cells. Despite their clinical success, there have been reports of TCEs driving systemic toxicity, non-specific T-cell activation, on-target off-tumor effects, and severe inflammation due to cytokine release. To address these limitations, we designed multivalent TCEs using Chemically Self-Assembled Nanorings (CSANs) that target the α/β constant region of the T-cell receptor (TCR) in the TCR/CD3 complex using a moderate affinity αTCR nanobody (αTCR

Indexed as

affinityimmunotherapyNanobodysolid tumorsspecificityT-cell engagerT-cell receptor

Identifiers

PMID42239270
PMCPMC13228493

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.